Covered recipient · General Payments record
HANS H HERFARTH
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$19,041.44
14 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $11,830.00 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000.00 | 1 |
| Travel and Lodging | $1,045.86 | 4 |
| Food and Beverage | $165.58 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $7,211.44 | 6 |
| Gilead Sciences, Inc. | $5,200.00 | 4 |
| Janssen Biotech, Inc. | $3,750.00 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,880.00 | 1 |
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HANS H HERFARTH
NPI 1538246574 · CMS profile ID 748946
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
CHAPEL HILL, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538246574?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538246574?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538246574?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1538246574?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
14 matching records · $19,041.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–14 of 14.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $1,250.00 | 09/30/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719162989 | CMS |
| Janssen Biotech, Inc. | $1,250.00 | 08/13/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719162987 | CMS |
| Janssen Biotech, Inc. | $1,250.00 | 07/03/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719162985 | CMS |
| Gilead Sciences, Inc. | $800.00 | 06/24/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743816007 | CMS |
| Gilead Sciences, Inc. | $1,200.00 | 06/24/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743816009 | CMS |
| Gilead Sciences, Inc. | $2,000.00 | 05/27/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743816005 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,880.00 | 05/26/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720913023 | CMS |
| PFIZER INC. | $6,000.00 | 02/10/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743224893 | CMS |
| PFIZER INC. | $44.00 | 01/28/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743062653 | CMS |
| PFIZER INC. | $289.00 | 01/16/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743805829 | CMS |
| PFIZER INC. | $193.24 | 01/16/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743805831 | CMS |
| PFIZER INC. | $519.62 | 01/16/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743805833 | CMS |
| PFIZER INC. | $165.58 | 01/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743805835 | CMS |
| Gilead Sciences, Inc. | $1,200.00 | 01/06/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743816003 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,575.00 | 2 |
| PY2025 | Principal investigator | $12,323.55 | 21 |
| PY2024 | Recipient | $319,533.00 | 4 |
| PY2024 | Principal investigator | $59,545.89 | 24 |
| PY2023 | Principal investigator | $224,917.53 | 43 |
| PY2022 | Principal investigator | $370,819.65 | 53 |
| PY2021 | Principal investigator | $392,748.05 | 56 |
| PY2020 | Principal investigator | $481,918.70 | 51 |
| PY2019 | Recipient | $4,200.00 | 1 |
| PY2019 | Principal investigator | $373,860.96 | 46 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $17,457.72 | 12/23/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 654263813 |
| Principal investigator 1 | AbbVie, Inc. | $2,070.00 | 12/18/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581509 |
| Principal investigator 1 | AbbVie, Inc. | $6,649.60 | 12/03/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581511 |
| Principal investigator 1 | Eli Lilly and Company | $286.00 | 11/30/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER, OPEN-LABEL, POST MARKETING CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS AND ERYTHRODERMIC PSORIASIS | No dispute reported | 06/30/2026 | 654285353 |
| Principal investigator 1 | Eli Lilly and Company | $286.00 | 11/30/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654285845 |
| Principal investigator 1 | AbbVie, Inc. | $1,465.60 | 11/04/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581513 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,774.30 | 10/16/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU | No dispute reported | 06/30/2026 | 686167251 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $150.30 | 10/15/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Patients with Ulcerative Colitis UC | No dispute reported | 06/30/2026 | 686167167 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,007.36 | 10/07/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 654263811 |
| Principal investigator 1 | AbbVie, Inc. | $1,350.40 | 09/30/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581507 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,628.00 | 09/17/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis | No dispute reported | 06/30/2026 | 686167255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,114.00 | 09/02/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 654263809 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,336.00 | 08/12/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis | No dispute reported | 06/30/2026 | 686167157 |
| Principal investigator 1 | AbbVie, Inc. | $2,700.80 | 08/08/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581547 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,247.28 | 07/29/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 654263807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/18/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 654263805 |
| Principal investigator 1 | AbbVie, Inc. | $10,000.00 | 07/16/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M16-000 | No dispute reported | 06/30/2026 | 647581515 |
| Principal investigator 1 | AbbVie, Inc. | $6,777.60 | 07/02/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581541 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 07/01/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU | No dispute reported | 06/30/2026 | 686167253 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,035.00 | 06/17/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | SC P3 CD Study | No dispute reported | 06/30/2026 | 686167161 |
| Principal investigator 1 | AbbVie, Inc. | $1,465.60 | 05/29/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581533 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 05/24/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 654263803 |
| Recipient | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,200.00 | 05/20/2019 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED OPS-2071 FOR 12 WEEKS IN SUBJECTS WITH CROHNS DISEASE SHOWING SYMPTOMS OF ACTIVE INFLAMMATION DESPITE ONGOING TREATMENT | No dispute reported | 06/30/2026 | 696049961 |
| Principal investigator 1 | Bausch Health US, LLC | $2,325.00 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA | A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHNS DISEASE | No dispute reported | 06/30/2026 | 684363449 |
| Principal investigator 1 | AbbVie, Inc. | $6,777.60 | 05/06/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581535 |
| Principal investigator 1 | AbbVie, Inc. | $1,350.40 | 03/26/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581519 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 03/18/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 654263801 |
| Principal investigator 1 | AbbVie, Inc. | $1,856.00 | 03/13/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581521 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $334.00 | 03/13/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Patients with Ulcerative Colitis UC | No dispute reported | 06/30/2026 | 686167165 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $334.00 | 03/11/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | SC P3 CD Study | No dispute reported | 06/30/2026 | 686167159 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 03/07/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHAPEL | P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU | No dispute reported | 06/30/2026 | 686167163 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,600.00 | 02/25/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL | A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 654263799 |
| Principal investigator 1 | AbbVie, Inc. | $2,700.80 | 02/01/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581517 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654285065 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A 24-WEEK MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO FUMARIC ACID ESTERS AND METHOTREXATE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE NAIVE TO SYSTEMIC TREATMENT WITH AN EXTENSION PERIOD | No dispute reported | 06/30/2026 | 654285067 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | No dispute reported | 06/30/2026 | 654285077 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 16 WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN TNFI EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 654285113 |
| Principal investigator 1 | Eli Lilly and Company | $396.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 654285191 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654285213 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | No dispute reported | 06/30/2026 | 654285217 |
| Principal investigator 1 | Eli Lilly and Company | $396.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654285219 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BDMARD-NAIVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 654285221 |
| Principal investigator 1 | Eli Lilly and Company | $110.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB LY2439821 IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 654285291 |
| Principal investigator 1 | Eli Lilly and Company | $396.00 | 01/22/2019 | Covered Recipient Teaching Hospital CLEVELAND CLINIC HOSPITAL | A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN CHINESE PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 654285831 |
| Principal investigator 1 | PFIZER INC. | $250,000.00 | 01/14/2019 | Non-covered Recipient Entity UNIVERSITY OF NORTH CAROLINA | EFFICACY OF TOFACITINIB IN PATIENTS WITH UC | No dispute reported | 06/30/2026 | 671686427 |
| Principal investigator 1 | AbbVie, Inc. | $2,498.00 | 01/10/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581525 |
| Principal investigator 1 | AbbVie, Inc. | $1,465.60 | 01/03/2019 | Non-covered Recipient Entity University Of North Carolina At Chapel Hill | M14-327 | No dispute reported | 06/30/2026 | 647581527 |